AI, Biotech, Pharmaceutical, sports, travel, photo, 生物医药, 用药常识, 健康知识, 数码, 影评
Anywhere
Joined May 2011
- Tweets1.3K
- Following2.6K
- Followers2.3K
- Likes1.8K
首付款12.75亿美元，吉利德将收购瀚辰星泰口服IL-23R抑制剂项目
HCXT-2001是一种临床阶段的试验性口服大环肽抑制剂，具有较长的半衰期
主要用于治疗炎症性肠病
瀚辰星泰（PepStar）这家公司才成立3年
就有了这么重磅的BD，太厉害了
Moderna/Merck 个体化 mRNA 癌疫苗三期详细数据公布：
复发或死亡风险降 42%
达到主要终点，但未超越华尔街过高预期，
Moderna 与 Merck 股价双双下跌——属于典型的"卖预期"反应。
和铂医药-B：巴托利单抗注射液(皮下注射)获NMPA批准上市用于治疗全身型重症肌无力
这是和铂医药首款获批上市的品种
巴托利单抗在大中华区(包括中国大陆、香港、澳门和台湾)的商业化由石药集团子公司负责
抖音上李老师说
人遇到危险的时候在那一刻
你可能已经死了
危险过后
你发现你还活着
可能是另一个平行世界
我在小时候得过一场重病
被推进手术室
等我出来的时候我发现我还活着
但是我可能已经不是那个我了
当然了，平行世界是否存在我不知道
这个说法有没有道理我也不知道
康方的美国合作伙伴Summit即将在美国进行依沃昔单抗的晚期胆道癌一线治疗的II/III 期临床。
预祝成功！
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
businesswire.com/news/home/2…
礼来三靶点激动剂治疗阻塞性睡眠呼吸暂停两项3期临床结果积极
这个病就是睡觉打呼噜
呼吸机是现在最有效的
以后打针就可以了
Presented at #SleepEurope2026:
In two phase 3 trials involving participants with OSA and obesity or overweight with or without type 2 diabetes, treatment with retatrutide was found to result in greater decreases in the apnea–hypopnea index than placebo. Full results of the TRIUMPH-1-OSA and TRIUMPH-2-OSA trials: nej.md/4BmAHOI
@ESRS_Sleep
![A graph from the Original Article “Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.” The names of the two trials, TRIUMPH-1-OSA and TRIUMPH-2-OSA, are in parentheses after the title. The graph] shows the change in AHI among participants in TRIUMPH-1-OSA. The trial results are being presented at the European Sleep Research Society 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.](https://pbs.twimg.com/media/HVIgx-QXsAAXxRZ.jpg?name=orig)
ALT A graph from the Original Article “Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.” The names of the two trials, TRIUMPH-1-OSA and TRIUMPH-2-OSA, are in parentheses after the title. The graph] shows the change in AHI among participants in TRIUMPH-1-OSA. The trial results are being presented at the European Sleep Research Society 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
